Get the Stockscreener App
0.8478
3.90%
-0.0344
Pre-market:
.83
-0.0178
-2.10%
Evogene Ltd stock is traded at $0.8478, with a volume of 109.79K.
It is down -3.90% in the last 24 hours and down -3.30% over the past month.
Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules, and genetic elements as the core components for such products. It holds several subsidiaries utilizing the CPB platform for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits, and ag-solutions for castor oil production. It generates maximum revenue from the Agriculture segment, followed by Industry.
See More
Previous Close:
$0.8822
Open:
$0.8854
24h Volume:
109.79K
Relative Volume:
0.25
Market Cap:
$7.39M
Revenue:
$3.95M
Net Income/Loss:
$-14.59M
P/E Ratio:
-0.7292
EPS:
-1.1626
Net Cash Flow:
$-14.46M
1W Performance:
-0.01%
1M Performance:
-3.30%
6M Performance:
-23.62%
1Y Performance:
-38.34%
1-Day Range:
$0.8103
$0.9002
1-Week Range:
$0.8103
$0.97
52-Week Range:
$0.73
$2.42
Evogene Ltd Stock (EVGN) Company Profile
Compare EVGN vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EVGN
Evogene Ltd
|
0.8478 | 7.39M | 3.95M | -14.59M | -14.46M | -1.1626 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Evogene Ltd Stock (EVGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-08-21 | Initiated | ROTH Capital | Buy |
| Jul-29-21 | Initiated | Aegis Capital | Buy |
| Dec-01-20 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-16-13 | Initiated | Oppenheimer | Outperform |
Evogene Ltd Stock (EVGN) Latest News
Evogene Ltd Stock Faces Pressure Amid Biotech Sector Volatility and Pipeline Delays in 2026 - AD HOC NEWS
Evogene Earnings Call: AI Ambition Meets Cash Reality - TipRanks
If You Invested $1,000 in Evogene (EVGN) - Stock Titan
EVGN PE Ratio & Valuation, Is EVGN Overvalued - Intellectia AI
Evogene (EVGN) director Leon Recanati details share and option holdings - Stock Titan
Evogene (EVGN) director Nir details multiple stock option grants in Form 3 - Stock Titan
Evogene (EVGN) director details stock option grants and vesting - Stock Titan
Evogene (EVGN) chief development officer reports 40,000-share stock option grant - Stock Titan
[Form 3] Evogene Ltd. Initial Statement of Beneficial Ownership - Stock Titan
Evogene (EVGN) director Sarit Firon details long-dated stock option grants - Stock Titan
Evogene (EVGN) CFO details RSU and stock option holdings - Stock Titan
Evogene (EVGN) CEO Haviv Ofer details multi-year stock option grants - Stock Titan
Evogene Ltd Stock (ISIN: IL0010831684) Faces Biotech Volatility Amid AI-Driven Crop Innovation Push - AD HOC NEWS
Evogene Ltd (EVGN) Q4 2025 Earnings Call Highlights: Strategic Shifts Amid Revenue Decline By GuruFocus - Investing.com Canada
Evogene (EVGN) Stock Analysis Report | Ratings, Financials & Performance - Benzinga Japan
Evogene outlines ChemPass AI-driven strategy and anticipates new collaborations amid organizational realignment - MSN
Evogene to Present Its Pharma Discovery Achievements at BIO-Europe Spring 2026 - Sahm
How Evogene uses AI to design drugs, on show at BIO-Europe 2026 - Stock Titan
Evogene Ltd. (NASDAQ:EVGN) Q4 2025 Earnings Call Transcript - Insider Monkey
Evogene Financial Results: Quarterly and Annual ReportNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
Evogene Ltd. Q4 2025 Earnings Call Summary - Yahoo Finance
Evogene: Q4 Earnings Snapshot - theheraldreview.com
Evogene earnings missed by $0.20, revenue topped estimates - Investing.com Australia
Evogene Q4 2025 Earnings Call Transcript - MarketBeat
Why Did EVGN Shares Drop More Than 14% Today? - Stocktwits
Earnings call transcript: Evogene’s Q4 2025 highlights restructuring gains - Investing.com
Earnings call transcript: Evogene’s Q4 2025 highlights restructuring gains By Investing.com - Investing.com India
Evogene Reports Fourth Quarter and Full Year 2025 Financial Results - Sahm
Evogene Reports Fourth Quarter and Full Year 2025 Financial Resu - GuruFocus
Evogene Reshapes AI-Driven Molecule Business With 2025 Results and Strategic Overhaul - TipRanks
EVOGENE ($EVGN) Releases Q4 2025 Earnings - Quiver Quantitative
Evogene Earnings Review: Q4 Summary - Benzinga
An Overview of Evogene's Earnings - Benzinga
Evogene Ltd expected to post a loss of 26 cents a shareEarnings Preview - TradingView
EVGN Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
EVGN Should I Buy - Intellectia AI
Is Evogene Ltd. stock heavily shortedJuly 2025 Retail & Reliable Trade Execution Plans - mfd.ru
Evogene refocuses on AI drug discovery platform ChemPass By Investing.com - Investing.com India
Evogene Details 2025 Strategic Refocus Around ChemPass AI and Core Health, Agriculture Markets - The Globe and Mail
Evogene refocuses on AI drug discovery platform ChemPass - Investing.com
Evogene Releases CEO Letter to Shareholders - Finviz
Evogene substantially completed divestment of non-core subsidiaries - marketscreener.com
Evogene (EVGN) pivots to ChemPass AI and core health and ag markets - Stock Titan
Fund Flows: Does Evogene Ltd have consistent dividend growth2025 Market WrapUp & AI Based Trade Execution Alerts - baoquankhu1.vn
Winners Losers: Is ProShares Trust ProShares UltraShort Consumer Staples likely to announce a buybackWeekly Stock Summary & Risk Adjusted Buy/Sell Alerts - baoquankhu1.vn
CEO Moves: Is Evogene Ltd in a consolidation phaseJuly 2025 PostEarnings & Expert-Curated Trade Recommendations - baoquankhu1.vn
Evogene Schedules Fourth Quarter and Full Year 2025 Financial Re - GuruFocus
Evogene Schedules Fourth Quarter and Full Year 2025 Financial Results Release – Company Announcement - Financial Times
Evogene and QUT partner on AI-based cancer therapies - Pharmaceutical Business review -
Ideas Watch: Is Huntington Ingalls Industries Inc a good stock for dollar cost averaging2025 Price Targets & Entry and Exit Point Strategies - baoquankhu1.vn
Evogene Ltd Stock (EVGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):